Genetic Disorders/Rare Disease
The development of recombinant factor VIII products has revolutionized the care of people with Hemophilia. At ARG, we know the science inherent in these clinical trials, and we know the market: the unlimited production of recombinant FVIII products is an opportunity ensure that the limited availability of plasma-derived FVIII concentrates does not reduce market potential of therapies.
Atlantic Research Group is adept at patient enrollment for Hemophilia studies. Due to ultra-low hemophilia patient populations, this expertise is critical for any CRO to succeed at bringing a therapy to those suffering from this life-altering condition.